Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition.
C57BL/6J mice infected with Plasmodium berghei ANKA develop neurological dysfunction and die within 7 days of infection. We show that treatment of infected mice with a kynurenine-3-hydroxylase inhibitor prevents them from developing neurological symptoms and extends their life span threefold until severe anemia develops.
Clark
Catherine J
CJ
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, United Kingdom. cc30r@clinmed.gla.ac.uk
Mackay
Gillian M
GM
Smythe
George A
GA
Bustamante
Sonia
S
Stone
Trevor W
TW
Phillips
R Stephen
RS
D000818:Animals; D054407:Chemokine CCL4; D004195:Disease Models, Animal; D007737:Kynurenine / Q000378:metabolism*; D050601:Kynurenine 3-Monooxygenase; D019402:Macrophage Inflammatory Proteins / Q000378:metabolism; D016779:Malaria, Cerebral / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D008810:Mice, Inbred C57BL; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D010848:Picolinic Acids / Q000378:metabolism; D010962:Plasmodium berghei; D013449:Sulfonamides / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D062367:ortho-Aminobenzoates / Q000378:metabolism
D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins; D010848:Picolinic Acids; C110196:Ro 61-8048; D013449:Sulfonamides; D013844:Thiazoles; D062367:ortho-Aminobenzoates; C031385:anthranilic acid; D007737:Kynurenine; D006899:Mixed Function Oxygenases; D050601:Kynurenine 3-Monooxygenase; C030614:picolinic acid